Prostate Carcinoma
Conditions
Brief summary
This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.
Detailed description
PRIMARY OBJECTIVE: I. To assess perceived usefulness of a virtual genetics board. SECONDARY OBJECTIVE: I. To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge. OUTLINE: Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
Interventions
OTHEREducational Intervention
Attend virtual genetics board
OTHERSurvey Administration
Complete survey
OTHERInterview
Complete interview
Sponsors
Thomas Jefferson University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study: * Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer. * Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers) * Scientists and researchers * Advocacy or patient stakeholder organization members
Exclusion criteria
• Non-medical providers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Likert scaled perceived usefulness scores of the virtual genetics board | After virtual genetics board | Perceived usefulness will be judged against a benchmark mean score of 5/7. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Means or changes in means of Likert scaled acceptability/feasibility | Before and after virtual genetics board | Will be summarized by means, standard deviations, and 95% confidence intervals. |
| Perceived ease of use | After virtual genetics board | Will be summarized by means, standard deviations, and 95% confidence intervals. |
| Self-efficacy for recommendations | Before and after virtual genetics board | Will be summarized by means, standard deviations, and 95% confidence intervals. |
| Change in mean scores on 17 genetics knowledge test questions | Baseline up to post-virtual genetics board | Will be summarized by means, standard deviations, and 95% confidence intervals. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAmy Leader, DrPH, MPH
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Outcome results
None listed